Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period from January 1, 2005, to June 30, 2005. The document serves as a Schedule 5 Blocklisting Six Monthly Return submitted to the UK Listing Authority and the Financial Services Authority. It details the status of various employee share option schemes and the number of shares issued or allotted under these plans during the six-month period.
Key Financial Metrics
The filing text does not provide data regarding revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory report on share scheme administration and blocklisting.
Key share-related metrics reported include:
- Total Shares in Issue: 5,943,249,825 (confirmed at the end of the period).
- Share Schemes Reported: Nine distinct schemes, including the GlaxoSmithKline Savings Related Share Option Scheme, Share Option Plan (ADS and Ordinary Shares), Glaxo Group Limited Share Option Scheme, and various legacy SmithKline Beecham and Glaxo Wellcome plans.
- Shares Issued/Allotted (Selected Schemes):
- GlaxoSmithKline Share Option Plan - ADS: 1,417,882
- Glaxo Wellcome International Share Option Scheme: 1,311,688
- Glaxo Group Limited Share Option Scheme: 1,225,136
- SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - ADS: 649,235
Material Changes
The filing reports the issuance and allotment of shares under multiple schemes during the first half of 2005. Notable changes include:
- Significant issuance under the GlaxoSmithKline Share Option Plan - ADS (1,417,882 shares) and the Glaxo Wellcome International Share Option Scheme (1,311,688 shares).
- The Glaxo Wellcome 1999 Share Option Plan reported zero shares issued or allotted during the period, with a remaining balance of 40,000 shares.
- One scheme, the GlaxoSmithKline Share Option Plan - Ordinary Shares, reported a negative balance of shares not yet issued/allotted at the end of the period (-189,395), indicating a specific accounting adjustment or over-allotment relative to the scheme's initial blocklisting.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. The document is a statutory return focused solely on the mechanics of share option schemes and blocklisting compliance.
Important Facts for Investors to Verify
- Verify the impact of the 1,417,882 ADS shares and 1,311,688 International Scheme shares issued during the period on overall dilution.
- Confirm the reason for the negative balance (-189,395) reported for the GlaxoSmithKline Share Option Plan - Ordinary Shares.
- Review the total outstanding shares in issue (5,943,249,825) against the company's latest financial statements to ensure consistency.
- Note that this filing contains no financial performance data; investors must refer to Form 20-F or interim financial reports for revenue and profit metrics.